Use of Gastric Acid–Suppressive Agents and the Risk of Community-Acquired Clostridium difficile–Associated Disease
By D. R. Snydman. 2006
870 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/458270f361832303d1268c3b163652c4fd53c585
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- M. Bauer
- J. Freeman
- J. Bartlett
- J. Corver
- R. Owens
- M. Wilcox
- C. Donskey
- E. Kuijper
Citations in the corpus
- Development and Validation of a Clostridium difficile Infection Risk Prediction Model (2011, background): “Primary risk factors for CDI include receipt of antimicrobials, older age, high severity of illness, exposure to other patients with CDI, and receipt of gastric acid suppressants.(10-17) Despite the breadth and depth of knowledge about risk factors available in the medical literature, healthcare fac”
- Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). (2018, unknown): “…a number of studies have suggested an epidemiologic association between use of stomach acid– suppressing medications, primarily PPIs, and CDI [37, 60, 116–119], results of other well-controlled studies suggest this association is the result of confounding with the underlying severity of illness,…”
- Narrative Review: The New Epidemic of Clostridium difficileAssociated Enteric Disease (2006, background): “A recent report implicates gastric acid–suppressive agents as a risk for disease (19), but this has not been consistently observed (20).”
- Antimicrobial-associated risk factors for Clostridium difficile infection. (2008, background): “One characteristic that these patients seem to share is that they are more likely to have received proton-pump inhibitors (PPIs) [34, 37, 38].”
- The Changing Epidemiology of Clostridium difficile Infections (2010, background): “(52) found that inflammatory bowel disease (relative risk”
- Emergence of Clostridium difficile-associated disease in North America and Europe. (2006, background): “difficile in patients diagnosed by their general practitioners had increased from fewer than one case per 100 000 in 1994 to 22 cases per 100 000 in 2004, but these preliminary data require verification in this patient population, with appropriate diagnostic tests for CDAD and collection of clinical”